Ekofuril 0.2 N16 capsules

Dosage form

Hard gelatin capsules, yellow

the contents of the capsules are yellow powder.

Structure

Active ingredient: nifuroxazide 200 mg.

Excipients: lactulose - 300 mg, microcrystalline cellulose - 58 mg, potato starch - 18 mg, magnesium stearate - 6 mg, sucrose - until the mass of the capsule contents is 630 mg.

Composition of a hard gelatin capsule: gelatin - up to 100%, water - 14-15%

cap: crimson dye [Ponso 4R] - 0.079801%, patented blue dye - 0.00165%, sunset dye - 0.093301%, titanium dioxide - 0.813158%

body: quinoline yellow dye - 0.583356%, sunset dye - 0.002565%, titanium dioxide - 0.974035%.

general description

Antimicrobial agent - nitrofuran

Special conditions

When treating diarrhea concurrently with nifuroxazide therapy, rehydration therapy (oral or intravenous) should be carried out in accordance with the patient's condition and the duration of the diarrhea.

During therapy with nifuroxazide, alcohol is not allowed.

Influence on the ability to drive vehicles and use mechanisms

The drug does not adversely affect the ability to drive vehicles and / or other mechanisms.

Drug interactions

Concomitant use of ethanol may cause hypersensitivity symptoms

Pharmacodynamics

Broad-spectrum antimicrobial agent - 5-nitrofuran derivative for the treatment of gastrointestinal infections.

Nifuroxazide blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and other biochemical reactions in the bacterial cell.

Destroys the membranes of sensitive bacteria, reduces the production of toxins by microorganisms.

It activates immunity, increases the activity of phagocytes and the titer of complement.

Effective against gram-positive microorganisms: Staphylococcus spp., Streptococcus spp .

gram-negative microorganisms: Salmonella spp., Klebsiella spp., Enterobacter spp., Escherichia coli, Shigella spp., Proteus spp., Haemophilus influenzae, Campilobacter spp., Edwarsiella spp., Citrobacter spp., Yibrioersin cholerae enter

Pharmokinetics

Nifuroxazide does not affect the state of the normal microflora of the human intestine.

In case of acute bacterial diarrhea, it restores intestinal eubiosis.

When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

After oral administration, nifuroxazide is practically not absorbed from the gastrointestinal tract and has no systemic effect.

Antibacterial activity against susceptible species of bacteria is shown only in the intestinal lumen.

It is excreted unchanged by the intestines.

The rate of elimination depends on the dose of the drug and gastrointestinal motility.

Indications

- acute and chronic diarrhea of ​​infectious genesis (without signs of helminthic invasion)

- chronic colitis and enterocolitis.

Contraindications

- hypersensitivity to nifuroxazide, other components of the drug, other derivatives of 5-nitrofuran

- deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption

- children's age up to 3 years (for this lekform).

There is no evidence of adverse effects on the fetus during pregnancy.

If necessary, with caution, the drug can be prescribed to pregnant women and women who are breastfeeding.

Side effects

Possibly: allergic reactions.

Dosage

200mg

Indications

- acute and chronic diarrhea of ​​infectious genesis (without signs of helminthic invasion)

- chronic colitis and enterocolitis.

INN / Active ingredient

Nifuroxazide

Contraindications

Hypersensitivity to nifuroxazide, other components of the drug, other derivatives of 5-nitrofuran

deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption

children's age up to 3 years (for this lekform)

Storage conditions and periods

In a place protected from moisture and light, at a temperature not exceeding 25 degrees.

Expiration date: 5 years

Specifications

Category

Diarrhea

Scope of the drug

Gastrointestinal tract

Release form

Capsules

Manufacturer country

Russia

Package quantity, pcs

16

Vacation conditions

Without recipe

Brand name

Avva Rus

The amount of the dosage form in the primary package

8 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Pharmaco-therapeutic group

Antimicrobial agent - nitrofuran

Anatomical and therapeutic characteristics

A07AX03 Nifuroxazide

Dosage form

Capsules

Dosage (volume) of the substance in the preparation

nifuroxazide 200.0 mg.

Expiration date in days

1825

Package weight, g

45